Rebound increases in chemokines by CXCR2 antagonist in breast cancer can be prevented by PKC delta and PKC epsilon activators

ERİN N., Tavsan E., Akdeniz O., Isca V. M. S., Rijo P.

CYTOKINE, vol.142, 2021 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 142
  • Publication Date: 2021
  • Doi Number: 10.1016/j.cyto.2021.155498
  • Journal Name: CYTOKINE
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Akdeniz University Affiliated: Yes

Abstract

Activation of CXCR2 by chemokines such as CXCL1 and CXCL2 increases aggressiveness of breast cancer, inducing chemoresistance, hence CXCR2 antagonists are in clinical trials. We previously reported that inhibition of CXCR2 increases MIP-2 (CXCL2), which may inhibit anti-tumoral effects of CXCR2 antagonists. This seems to be due to inhibition of protein kinase C (PKC) by CXCR2 antagonist since specific inhibitor of PKC also enhances MIP-2 secretion.